Treace Debuts SuperBite Screws with 2.5–7.0mm Range, Targets $300M Market Growth
Treace Medical Concepts completed first surgical cases using its headless SuperBite Compression Screw System, which offers self-drilling features and 2.5mm–7.0mm diameters for forefoot to hindfoot applications. Full commercialization is slated for Q3 2026 alongside the SpeedXM™ Midfoot Fusion launch, aiming to expand Treace’s addressable market by $300 million.
1. First Surgical Cases Completed
Treace Medical Concepts performed its inaugural surgical procedures using the SuperBite Compression Screw System, marking the first clinical application of the headless, variable‐pitch screws in fusion and osteotomy surgeries.
2. Advanced Design and Broad Applications
SuperBite screws incorporate variable thread pitch, optimized headless design, self‐drilling and countersinking features, and smoothed beveled heads, enabling rapid insertion in both minimally invasive and open procedures across the forefoot, midfoot, and hindfoot.
3. Commercialization Timeline and Market Impact
Full commercialization of SuperBite is slated for Q3 2026, coinciding with the SpeedXM™ Midfoot Fusion System launch; together these products are projected to expand Treace’s addressable market by $300 million and deepen engagement with over 3,300 foot and ankle surgeons.